In the TCGA database, FOXK2 showed decreased expression in tumor samples of glioblastoma multiforme (GBM), renal chromophobe (KICH), and renal clear cell carcinoma (KIRC) compared to the normal control group (p < 0.05) among the 33 cancer types. This evidence concerns the gene FOXK2 and neoplasm.